title: Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.
abstract: The DNA-damage response (DDR) pathways consist of interconnected components that respond to DNA damage to allow repair and promote cell survival. The DNA repair pathways and downstream cellular responses have diverged in cancer cells compared with normal cells because of genetic alterations that underlie drug resistance, disabled repair and resistance to apoptosis. Consequently, abrogating DDR pathways represents an important mechanism for enhancing the therapeutic index of DNA-damaging anticancer agents. In this review, we discuss the DDR pathways that determine antitumor effects of DNA-damaging agents with a specific focus on treatment outcomes in tumors carrying a defective p53 pathway. Finely tuned survival and death pathways govern the cellular responses downstream of the cytotoxic insults inherent in anticancer treatment. The significance and relative contributions of cellular responses including apoptosis, mitotic catastrophe and senescence are discussed in relation to the web of molecular interactions that affect such outcomes. We propose that promising combinations of DNA-damaging anticancer treatments with DDR-pathway inhibition would be further enhanced by activating downstream apoptotic pathways. The proposed rationale ensures that actual cell death is the preferred outcome of cancer treatment instead of other responses, including reversible cell cycle arrest, autophagy or senescence. Finally, to better measure the contribution of different cellular responses to anticancer treatments, multiplex in vivo assessments of therapy-induced response pathways such as cell death, senescence and mitotic catastrophe is desirable rather than the current reliance on the measurement of a single response pathway such as apoptosis.
authors.affiliation: Signal Transduction Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia. Fares.Al-Ejeh@qimr.edu.au
authors.forename: F
authors.initials: F
authors.lastname: Al-Ejeh
authors.forename: R
authors.initials: R
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Wiegmans
authors.forename: S R
authors.initials: SR
authors.lastname: Lakhani
authors.forename: M P
authors.initials: MP
authors.lastname: Brown
authors.forename: K K
authors.initials: KK
authors.lastname: Khanna
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D000071877:Checkpoint Kinase 1; D004249:DNA Damage; D004260:DNA Repair; D051747:DNA-Activated Protein Kinase / Q000037:antagonists & inhibitors; D006801:Humans; D008938:Mitosis; D023421:Models, Animal; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011494:Protein Kinases / Q000502:physiology; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011494:Protein Kinases; D000071877:Checkpoint Kinase 1; D051747:DNA-Activated Protein Kinase